EGFR and neoplasm: Furthermore, the antitumor effect observed in mice immunized with both murine and human ErbB3 receptors as antigens and subsequently challenged with a metastatic tumor resistant to an anti-EGFR MAb suggests the potential of vaccination with the Mv-HER3 candidate in the context of HER3-overexpressing carcinomas that have acquired resistance to antitumor therapies.